Regeneron Pharmaceuticals, Inc. REGN
788.04
(7.98)
(1.00%)
as of 25 Sep
- Market cap
- $81.3B
- P/E
- 18.8×
Follow REGN
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
Regeneron Pharmaceuticals, Inc. (REGN) Revenue
Regeneron Pharmaceuticals, Inc.'s revenue for fiscal 2025 was $14.3B, unchanged from fiscal 2024. Over the twelve months to 30 June 2026 it was $15.5B. Over the past ten years it has ranged from $4.1B (fiscal 2015) to $16.1B (fiscal 2021); the current reading is higher than 91% of that period. Revenue has risen for 3 consecutive fiscal years. Regeneron Pharmaceuticals, Inc. ranks 1st of 402 Biotechnology companies by revenue.
Revenue, annual
Annual
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $14.3B | 0.99% |
| FY2024 | $14.2B | 8.27% |
| FY2023 | $13.1B | 7.76% |
| FY2022 | $12.2B | (24.26%) |
| FY2021 | $16.1B | 89.14% |
| FY2020 | $8.5B | 29.58% |
| FY2019 | $6.6B | 27.44% |
| FY2018 | $5.1B | (12.37%) |
| FY2017 | $5.9B | 20.82% |
| FY2016 | $4.9B | 18.44% |
Quarterly
| Period | Revenue | Change |
|---|---|---|
| Jun 2026 | $4.3B | 19.01% |
| Mar 2026 | $3.6B | (7.18%) |
| Dec 2025 | $3.9B | 3.46% |
| Sep 2025 | $3.8B | 2.14% |
| 42 more quarters | Free account |
Against its own ten years
Low $4.1B
High $16.1B
Ten-year median
$8.5B
Current reading's percentile
91
Revenue against peers
| Company | Revenue |
|---|---|
| REGN Regeneron Pharmaceuticals, Inc. | $15.5B |
| VRTX Vertex Pharmaceuticals Incorporated compare | $12.6B |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | $6.1B |
| ARGX argenex SE compare | $5.3B |
| ALNY Alnylam Pharmaceuticals, Inc. compare | $4.8B |
| RPRX Royalty Pharma PLC compare | $2.5B |
| MRNA Moderna, Inc. compare | $2.2B |
| INSM Insmed, Inc. compare | $1.1B |
| RVMD Revolution Medicines, Inc. compare | $26.9M |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on REGN
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement